JP6198278B2 - Ａａｖ調製物からの混入ウイルスの除去 - Google Patents

Ａａｖ調製物からの混入ウイルスの除去 Download PDF

Info

Publication number
JP6198278B2
JP6198278B2 JP2014529633A JP2014529633A JP6198278B2 JP 6198278 B2 JP6198278 B2 JP 6198278B2 JP 2014529633 A JP2014529633 A JP 2014529633A JP 2014529633 A JP2014529633 A JP 2014529633A JP 6198278 B2 JP6198278 B2 JP 6198278B2
Authority
JP
Japan
Prior art keywords
filter
sample
virus
baculovirus
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014529633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014526246A (ja
JP2014526246A5 (enExample
Inventor
ヴィルヘルムス テオドルス ヨハネス マリア クリスティアーン エルメンス，
ヴィルヘルムス テオドルス ヨハネス マリア クリスティアーン エルメンス，
ジェームズ パトリック スミス，
ジェームズ パトリック スミス，
Original Assignee
ユニキュアー アイピー ビー．ブイ．
ユニキュアー アイピー ビー．ブイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47832422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6198278(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ユニキュアー アイピー ビー．ブイ．, ユニキュアー アイピー ビー．ブイ． filed Critical ユニキュアー アイピー ビー．ブイ．
Publication of JP2014526246A publication Critical patent/JP2014526246A/ja
Publication of JP2014526246A5 publication Critical patent/JP2014526246A5/ja
Application granted granted Critical
Publication of JP6198278B2 publication Critical patent/JP6198278B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
    • B01D71/06—Organic material
    • B01D71/08—Polysaccharides
    • B01D71/10—Cellulose; Modified cellulose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/26—Further operations combined with membrane separation processes
    • B01D2311/2623—Ion-Exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/26—Further operations combined with membrane separation processes
    • B01D2311/2649—Filtration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14351—Methods of production or purification of viral material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Water Supply & Treatment (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2014529633A 2011-09-08 2012-09-07 Ａａｖ調製物からの混入ウイルスの除去 Expired - Fee Related JP6198278B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161532176P 2011-09-08 2011-09-08
US61/532,176 2011-09-08
EP11180594 2011-09-08
EP11180594.1 2011-09-08
PCT/NL2012/050619 WO2013036118A1 (en) 2011-09-08 2012-09-07 Removal of contaminating viruses from aav preparations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017125458A Division JP6624690B2 (ja) 2011-09-08 2017-06-27 Ａａｖ調製物からの混入ウイルスの除去

Publications (3)

Publication Number Publication Date
JP2014526246A JP2014526246A (ja) 2014-10-06
JP2014526246A5 JP2014526246A5 (enExample) 2015-10-01
JP6198278B2 true JP6198278B2 (ja) 2017-09-20

Family

ID=47832422

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014529633A Expired - Fee Related JP6198278B2 (ja) 2011-09-08 2012-09-07 Ａａｖ調製物からの混入ウイルスの除去
JP2017125458A Expired - Fee Related JP6624690B2 (ja) 2011-09-08 2017-06-27 Ａａｖ調製物からの混入ウイルスの除去

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017125458A Expired - Fee Related JP6624690B2 (ja) 2011-09-08 2017-06-27 Ａａｖ調製物からの混入ウイルスの除去

Country Status (19)

Country Link
US (3) US9840694B2 (enExample)
EP (3) EP2744895B1 (enExample)
JP (2) JP6198278B2 (enExample)
KR (1) KR101961347B1 (enExample)
CN (2) CN107502597A (enExample)
AU (1) AU2012304993B2 (enExample)
BR (1) BR112014005255A2 (enExample)
CA (1) CA2847604A1 (enExample)
DK (1) DK2744895T3 (enExample)
EA (1) EA027511B1 (enExample)
ES (1) ES2558168T3 (enExample)
HU (1) HUE026579T2 (enExample)
IL (1) IL231398A (enExample)
MX (1) MX349601B (enExample)
PL (1) PL2744895T3 (enExample)
PT (1) PT2744895E (enExample)
SI (1) SI2744895T1 (enExample)
WO (1) WO2013036118A1 (enExample)
ZA (1) ZA201401714B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6198278B2 (ja) 2011-09-08 2017-09-20 ユニキュアー アイピー ビー．ブイ． Ａａｖ調製物からの混入ウイルスの除去
CN105745326A (zh) 2013-10-24 2016-07-06 优尼科Ip有限公司 用于基因治疗神经疾病的aav-5假型载体
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
SG10202007103TA (en) 2014-11-05 2020-09-29 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CN112375760A (zh) 2014-11-14 2021-02-19 沃雅戈治疗公司 调节性多核苷酸
KR20230169197A (ko) 2014-11-14 2023-12-15 보이저 테라퓨틱스, 인크. 근위축성 측삭 경화증(als)을 치료하는 조성물 및 방법
EP3591070B1 (en) * 2014-11-28 2022-12-21 uniQure IP B.V. Dna impurities in a composition comprising a parvoviral virion
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
HUE043842T2 (hu) 2014-12-24 2019-09-30 Uniqure Ip Bv RNAi-indukált huntingtin gén szuppresszió
EP3054007A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
CN117904112A (zh) 2016-05-18 2024-04-19 沃雅戈治疗公司 调节性多核苷酸
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
CN119491003A (zh) 2017-05-05 2025-02-21 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
AU2018352236B2 (en) 2017-10-16 2025-04-10 The Curators Of The University Of Missouri Treatment of amyotrophic lateral sclerosis (ALS)
IL275838B2 (en) 2018-01-17 2024-11-01 Meiragtx Uk Ii Ltd A modified raav capsid protein for gene therapy
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
WO2020053258A1 (en) 2018-09-12 2020-03-19 Uniqure Ip B.V. Rnai induced c9orf72 suppression for the treatment of als/ftd
SG11202103151RA (en) 2018-09-28 2021-04-29 Voyager Therapeutics Inc Frataxin expression constructs having engineered promoters and methods of use thereof
CN112912518A (zh) * 2018-10-15 2021-06-04 再生生物股份有限公司 用于测量复制缺陷型病毒载体和病毒的感染性的方法
CA3119721A1 (en) 2018-11-19 2020-05-28 Uniqure Ip B.V. A companion diagnostic to monitor the effects of gene therapy
WO2020104480A1 (en) 2018-11-19 2020-05-28 Uniqure Biopharma B.V. Adeno-associated virus vectors for expressing fviii mimetics and uses thereof
AU2019382824A1 (en) 2018-11-19 2021-06-03 Uniqure Ip B.V. Method and means to deliver miRNA to target cells
US20200199625A1 (en) 2018-11-19 2020-06-25 Uniqure Ip B.V. RNAi induced reduction of ataxin-3 for the treatment of Spinocerebellar ataxia type 3
WO2020150556A1 (en) * 2019-01-18 2020-07-23 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
EP3924364A1 (en) 2019-02-15 2021-12-22 Sangamo Therapeutics, Inc. Compositions and methods for producing recombinant aav
WO2020219897A1 (en) * 2019-04-24 2020-10-29 Biogen Ma Inc. Methods for production of recombinant adeno-associated viruses
JP7681277B2 (ja) 2019-07-15 2025-05-22 メイラグティーエックス ユーケー アイアイ リミティド 関節炎疾患の治療のための修飾ａａｖキャプシドタンパク質
EP4031148A1 (en) 2019-09-16 2022-07-27 uniQure IP B.V. Targeting misspliced transcripts in genetic disorders
US20230020565A1 (en) 2019-12-04 2023-01-19 Sangamo Therapeutics, Inc. Novel compositions and methods for producing recombinant aav
CN114829371A (zh) * 2019-12-12 2022-07-29 Emd密理博公司 使用透析过滤缓冲液强化的病毒过滤
EP4097239A2 (en) * 2020-01-29 2022-12-07 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
EP4112735A4 (en) * 2020-02-28 2023-09-06 Asahi Kasei Medical Co., Ltd. Method for evaluating viral clearance performance
EP4133074A1 (en) 2020-04-07 2023-02-15 uniQure IP B.V. Gene constructs for silencing angiopoietin-like 3 (angptl3) and uses thereof
CN115427561B (zh) 2021-03-09 2024-06-04 辉大(上海)生物科技有限公司 工程化CRISPR/Cas13系统及其用途
US20240157306A1 (en) * 2021-03-30 2024-05-16 3M Innovative Properties Company Hollow-fiber membrane and method making thereof
CN117120152A (zh) * 2021-03-30 2023-11-24 3M创新有限公司 包含聚砜和聚噁唑啉的中空纤维膜及其制造方法
WO2022214635A1 (en) 2021-04-08 2022-10-13 Stichting Vu Nucleic acid molecules for compensation of stxbp1 haploinsufficiency and their use in the treatment of stxbp1-related disorders
CA3219847A1 (en) 2021-06-02 2022-12-08 Sander Jan Hendrik Van Deventer Adeno-associated virus vectors modified to bind high-density lipoprotein
US20250382611A1 (en) 2021-06-21 2025-12-18 Uniqure Biopharma B.V. Gene constructs for silencing alpha-synuclein and uses thereof
EP4359010A1 (en) 2021-06-21 2024-05-01 uniQure biopharma B.V. Improved lysis procedures
WO2023283962A1 (en) 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
WO2023198663A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of snca
CN119032174A (zh) 2022-04-12 2024-11-26 优尼科生物制药有限公司 ApoE的核酸调节
EP4508215A1 (en) 2022-04-12 2025-02-19 uniQure biopharma B.V. Novel systems for nucleic acid regulation
EP4508214A1 (en) 2022-04-12 2025-02-19 uniQure biopharma B.V. Nucleic acid regulation of c9orf72
US20240209324A1 (en) * 2022-12-22 2024-06-27 Cytiva Us Llc Virus separation
AU2024256392A1 (en) 2023-04-18 2025-10-23 Uniqure Biopharma B.V. Gene delivery vehicles comprising rna and antibodies
AU2024258047A1 (en) 2023-04-18 2025-10-23 Uniqure Biopharma B.V. Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs
AU2024313758A1 (en) 2023-06-23 2026-01-08 Uniqure Biopharma B.V. Novel fragile x constructs
WO2025051805A1 (en) 2023-09-04 2025-03-13 Uniqure Biopharma B.V. Novel neurotropic recombinant adeno-associated virus particles
WO2025078602A1 (en) 2023-10-11 2025-04-17 Uniqure Biopharma B.V. Nucleic acid regulation of msh3 in repeat expansion disorders
WO2025078606A1 (en) 2023-10-11 2025-04-17 Uniqure Biopharma B.V. Further novel systems for nucleic acid regulation
WO2025078598A1 (en) 2023-10-11 2025-04-17 Uniqure Biopharma B.V. Novel nucleic acid regulation of huntingtin gene
WO2025114524A1 (en) 2023-11-30 2025-06-05 Uniqure Biopharma B.V. Formulations for viral drug products
WO2025219443A1 (en) 2024-04-19 2025-10-23 Uniqure Biopharma B.V. Nucleic acid for a1at regulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US6066324A (en) 1994-10-07 2000-05-23 Loyola University Of Chicago Carboxyl terminal of papilloma virus L1 region is not required for formation of virus-like particles
DE19709186C2 (de) 1997-03-06 1999-10-14 Medigene Ag Filtrationsverfahren zur Trennung von Viren
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6593123B1 (en) * 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
WO2003074714A1 (en) 2002-03-05 2003-09-12 Stichting Voor De Technische Wetenschappen Baculovirus expression system
US20050009168A1 (en) * 2003-05-12 2005-01-13 Robbins Joan Marie Methods and apparatus for Adeno associated virus purification
CA2655957C (en) * 2006-06-21 2016-05-03 Amsterdam Molecular Therapeutics (Amt) B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
US20080299545A1 (en) * 2007-03-06 2008-12-04 Shuyuan Zhang Chromatographic methods for assessing adenovirus purity
US20100323429A1 (en) * 2008-04-10 2010-12-23 Yu-Chen Hu Methods for purifying baculovirus
ES2693194T3 (es) * 2009-06-16 2018-12-10 Genzyme Corporation Métodos mejorados para la purificación de vectores de AAV recombinantes
JP2013517798A (ja) * 2010-01-28 2013-05-20 ザ チルドレンズ ホスピタル オブ フィラデルフィア ウイルスベクター精製における拡張可能な製造プラットフォームおよび遺伝子治療における使用のための高純度ウイルスベクター
JP6198278B2 (ja) * 2011-09-08 2017-09-20 ユニキュアー アイピー ビー．ブイ． Ａａｖ調製物からの混入ウイルスの除去

Also Published As

Publication number Publication date
PL2744895T3 (pl) 2016-04-29
JP2018023365A (ja) 2018-02-15
EP2990477A1 (en) 2016-03-02
JP6624690B2 (ja) 2019-12-25
US20190218523A1 (en) 2019-07-18
EP2744895B1 (en) 2015-10-14
HK1220229A1 (en) 2017-04-28
DK2744895T3 (en) 2016-01-04
KR20140074333A (ko) 2014-06-17
CN103857790B (zh) 2017-09-08
US10253301B2 (en) 2019-04-09
US9840694B2 (en) 2017-12-12
KR101961347B1 (ko) 2019-03-25
EA201490583A1 (ru) 2014-07-30
EP2990477B1 (en) 2018-08-29
US20180100143A1 (en) 2018-04-12
SI2744895T1 (sl) 2016-03-31
AU2012304993B2 (en) 2017-09-14
IL231398A0 (en) 2014-04-30
US20140342434A1 (en) 2014-11-20
MX349601B (es) 2017-08-04
HUE026579T2 (en) 2016-06-28
EA027511B1 (ru) 2017-08-31
IL231398A (en) 2017-06-29
EP2990477B8 (en) 2018-10-31
PT2744895E (pt) 2016-02-08
ZA201401714B (en) 2015-12-23
JP2014526246A (ja) 2014-10-06
BR112014005255A2 (pt) 2017-04-04
AU2012304993A1 (en) 2014-03-20
ES2558168T3 (es) 2016-02-02
MX2014002733A (es) 2014-07-14
CA2847604A1 (en) 2013-03-14
EP2744895A1 (en) 2014-06-25
CN107502597A (zh) 2017-12-22
CN103857790A (zh) 2014-06-11
EP3425044A1 (en) 2019-01-09
WO2013036118A1 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
JP6198278B2 (ja) Ａａｖ調製物からの混入ウイルスの除去
CN112469822A (zh) 用于重组aav生产的阴离子交换色谱
US10501758B2 (en) Recombinant baculovirus and method for using the same for preparing recombinant adeno-associated virus vector
US20240141377A1 (en) Controlled expression of viral proteins
JP2020533973A (ja) 改変されたホスホリパーゼドメインを含むアデノ随伴ウイルス（ａａｖ）
KR20230011935A (ko) 아데노 연관 바이러스 입자 또는 아데노바이러스를 정제하기 위한 방법 및 조성물
US20200048641A1 (en) Methods for enhancing yield of recombinant adeno-associated virus
US20240287545A1 (en) Improved lysis procedures
HK1220229B (en) Removal of contaminating viruses from aav preparations
HK1262994A1 (en) Removal of contaminating viruses from aav preparations
Michalsky et al. Concentration of the baculovirus Autographa californica M nucleopolyhedrovirus (AcMNPV) by ultrafiltration
Michalsky et al. Purification of the baculovirus Autographa californica M nucleopolyhedrovirus by tangential flow ultrafiltration
WO2024054983A1 (en) Controlled expression of viral proteins
WO2024130163A1 (en) Methods for manufacturing viruses and viral particles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170614

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170725

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170818

R150 Certificate of patent or registration of utility model

Ref document number: 6198278

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees